ArticleBone marrow transplantation2016
Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy.
Article in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center.Clinical lymphoma, myeloma & leukemia · 2021Article
- Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma.Nature communications · 2020Article
- The impact of response kinetics for multiple myeloma in the era of novel agents.Blood advances · 2019Review
- Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse.Leukemia · 2019Article
- Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.Bone marrow transplantation · 2019Review
- Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.Journal of controlled release : official journal of the Controlled Release Society · 2018Article
- The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma.American journal of hematology · 2017Article
- The next generation of novel therapies for the management of relapsed multiple myeloma.Future oncology (London, England) · 2017Review
- The Progress of Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Multiple Myeloma (Review).Technology in cancer research & treatmentReview
- Second Autologous Hematopoietic Stem Cell Transplant as Salvage Therapy for Relapsed Multiple Myeloma: A Global Treatment Option for Eligible Patients.Acta haematologicaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
27064687What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.